Colorectal Cancer Screening with Gixam™
Gixam™ by Jubaan is a non-invasive, AI-powered pre-screening system designed to detect early warning signs of colorectal adenomas — the precursors to colorectal cancer — through oral microbiome analysis.
What Is Colorectal Cancer Screening?
Colorectal cancer (CRC) is one of the most common cancers worldwide, yet it is also one of the most preventable when caught early. Standard screening methods — such as colonoscopy and the fecal occult blood test (FOBT/FIT) — face significant barriers: patient discomfort, complex preparation requirements, and low compliance rates. These limitations mean that many people at risk simply do not get screened, resulting in late-stage diagnoses with poorer outcomes. The medical community has long sought a simpler, more accessible alternative that can be deployed at the point of care by primary care physicians, without sending patients to specialist labs or requiring invasive procedures.
How Gixam™ Works
Gixam™ is a compact, tabletop medical device placed in a physician's office. During a routine visit, the patient places their head into the unit and extends their tongue for a few seconds while the device captures multiple high-resolution images. Jubaan's proprietary artificial intelligence engine — built on deep learning and spectral image analysis — processes these images instantly. The system analyzes the oral microbiome signature visible on the tongue's surface, searching for biomarkers that correlate with the presence of adenomas in the colon. Within seconds, the physician receives a risk prediction that guides clinical decision-making: whether to proceed to confirmatory colonoscopy or continue with routine monitoring. No preparation, no sample collection, no waiting for lab results.
The Science Behind Oral Microbiome Analysis
Scientific research has established that systemic diseases, including gastrointestinal disorders, can manifest detectable changes in the oral cavity. The human microbiome — the vast community of bacteria and microorganisms living in and on the body — differs markedly between healthy individuals and those with gastrointestinal pathology. Specific bacterial species found on the tongue have been shown to distinguish patients with colorectal adenomas from healthy controls. Jubaan's technology harnesses this biological signal using spectral imaging algorithms that detect color and texture patterns in the tongue beyond what the human eye can perceive, then applies deep learning models trained on thousands of clinical samples to generate a reliable prediction. This combination of image analysis, microbiome science, and AI delivers a screening method that is both non-invasive and highly informative.
Clinical Advantages and Compliance
One of the most critical challenges in CRC prevention is patient compliance. Studies consistently show that a significant proportion of patients who are recommended for standard pre-screening tests never complete them, due to the invasive nature, embarrassment, or logistical complexity involved. Gixam™ removes these barriers entirely. Because the test is performed in the same setting as a standard medical appointment — in under a minute, with no preparation — patients are far more likely to participate. Higher compliance means more people are screened, more adenomas are caught at stage 0 before they progress to cancer, and ultimately more lives are saved. Jubaan's clinical studies, conducted in partnership with leading medical centers including NYU Langone and NewYork-Presbyterian Hospital, are validating Gixam™'s accuracy and reproducibility across diverse patient populations.
Regulatory Status and Research
Gixam™ is currently an investigational device undergoing clinical evaluation in the United States, Israel, and Europe. It is not yet approved for commercial use in any jurisdiction. Jubaan is actively pursuing regulatory clearance pathways and collaborating with gastroenterology research groups to build the evidence base required for regulatory approval. The company's network of clinical partners — spanning academic medical centers and gastroenterology practices across the United States and Israel — reflects the scientific community's growing interest in non-invasive CRC screening alternatives. As Jubaan advances through clinical development, Gixam™ represents a potential paradigm shift in how colorectal cancer is detected and prevented globally.